PI
NVCR icon

Putnam Investments’s NovoCure NVCR Stock Holding History

Putnam Investments’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-64,683
Closed -$4.36M – 907
2020
Q1 		$4.36M Sell
64,683
-180
-0.3% -$14.2K 0.01% 466
2019
Q4 		$5.47M Buy
+64,863
New +$5.24M 0.01% 490

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCP
Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return

Putnam Investments's NVCR Position: Q2 2020 in Review

Putnam Investments sold out of NovoCure (NVCR) in Q2 2020, closing a stake of 64,683 shares — an estimated $4.36M sold.

Putnam Investments first reported a position in NVCR in Q4 2019 and held it in 2 quarters. The position peaked at $5.47M in Q4 2019. 264 funds tracked by Wall St. Rank hold NVCR as of Q2 2020.

  • Putnam Investments reported no remaining NovoCure position as of Q2 2020 after selling out during the quarter.
  • Putnam Investments sold 64,683 NovoCure shares in Q2 2020, an estimated $4.36M.
  • Putnam Investments first reported a position in NovoCure in Q4 2019 and held it in 2 quarters.
  • Putnam Investments's NovoCure position peaked at $5.47M in Q4 2019.
  • 264 funds tracked by Wall St. Rank held NovoCure as of Q2 2020.

Based on Putnam Investments's 13F filing for Q2 2020, filed 14 Aug 2020.